SQI Diagnostics Submits FDA 510(k) and Health Canada Medical Device License Filings for its Automated SQiDworks Platform and QuantiSpot RA Microarray Consumable Test

TORONTO, Oct. 29 /CNW/ - SQI Diagnostics Inc. (TSX-Venture: SQD), a medical systems automation company focused on evolving laboratory-based biomarker testing, announced today that the United States Food and Drug Administration (FDA) has received the Company's 510(k) submission. The 510(k) is seeking marketing clearance in the United States from the FDA for SQI's automated SQiDworksTM platform and QuantiSpot RATM microarray consumable test.